Buy or sell Celldom, Inc stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Celldom, Inc Stock

Find and study cells that make diseases incurable

About Celldom, Inc Stock

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company’s TrapTx Analyzer System uniquely integrates both phenotypic and genomic data at massive scale (up to tens of thousands of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology.

Funding History

January 2017$225K
December 2017$225K
September 2018$1.5M

Management

Commercial Advisor

J. Kurt Jacobus

Scientific & Commercial Advisor

Myla Lai-Goldman

Technical Advisor - Systems Engineering

Emil Radulescu

Financial Advisor

Jeff Blake

Co-Founder, Chief Executive Officer

Benjamin Yellen

Co-Founder, President, & CEO

Zachary Forbes

Co-Founder

Kris Wood

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo